Table 3.
Clinical characteristics of isolated SMGN patients with and without NELL1 expression in glomerular immune deposits
| NELL1-positive | NELL1-negative | p value | |
|---|---|---|---|
| Patients, n | 58 | 77 | |
| Age, years | 40.0 (32.8–50.3) | 44.0 (33.0–52.0) | 0.574 |
| Male, n (%) | 13/58 (22.4) | 24/77 (31.2) | 0.259 |
| BUN, mmol/L | 4.0 (3.2–5.4) | 4.4 (3.5–6.2) | 0.220 |
| Serum creatinine, μmol/L | 56.0 (47.9–71.4) | 62.5 (53.3–79.5) | 0.068 |
| Serum albumin, g/L | 32.4 (24.1–36.7) | 22.5 (17.9–35.6) | 0.004 |
| eGFR, mL/min/1.73 m2 | 110.5 (97.9–122.7) | 105.4 (86.1–117.7) | 0.161 |
| Urine protein, g/day | 2.9 (1.4–4.4) | 3.9 (2.6–7.5) | 0.003 |
| No. of patients showing microscopic hematuria, % | 23/56 (41.1) | 30/71 (42.3) | 0.893 |
| No. of patients showing full nephrotic syndrome, % | 9/51 (17.6) | 30/63 (47.6) | 0.001 |
| No. of patients showing nephrotic range proteinuria, % | 16/46 (34.8) | 34/55 (61.8) | 0.007 |
| No. of patients showing hypoalbuminemia, % | 23/55 (41.8) | 52/74 (70.3) | 0.001 |
| Positive ANA (%) | 5/49 (10.2) | 15/53 (28.3) | 0.021 |
| Positive HBsAg (%) | 3/51 (5.9) | 3/68 (4.4) | 1.000 |
| No. of patients showing edema, % | 37/52 (71.2) | 56/73 (76.7) | 0.483 |
| No. of patients with eGFR<60 mL/min/1.73 m2, % | 9/56 (16.1) | 6/72 (8.3) | 0.177 |
| Cancer, % | 2/58 (3.4) | 2/77 (2.6) | 1.000 |